Drug Profile
PA 83 FhCMB
Alternative Names: PA83 FhCMB; Plant derived recombinant protective antigen anthrax vaccine; rPA anthrax vaccineLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator iBio Inc
- Developer Fraunhofer USA Center for Molecular Biotechnology
- Class Anthrax vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Anthrax(Prevention) in USA (Parenteral)
- 30 Nov 2015 iBio has patent protection for iBioModulator™ thermostable immunomodulator protein technology in China
- 01 Aug 2014 Phase-I clinical trials in Anthrax (Prevention) in USA (Parenteral) (NCT02239172)